Welcome to our dedicated page for Novanta SEC filings (Ticker: NOVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novanta Inc. (Nasdaq: NOVT) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a global supplier of core technology solutions for medical, life science, and advanced industrial OEMs. This SEC filings page brings together those disclosures so investors can review the company’s regulatory record in one place.
Among the most frequently referenced filings are current reports on Form 8-K, where Novanta announces quarterly financial results, provides non-GAAP metrics such as Adjusted EBITDA and Adjusted Diluted EPS, and discloses material events. Recent 8-K filings have covered results for specific fiscal quarters, revisions to financial guidance, changes in Board composition, and details of share repurchase authorizations.
Filings also document capital markets and financing transactions, including the underwriting agreement and terms of Novanta’s tangible equity units offering, which combines prepaid stock purchase contracts with senior amortizing notes due 2028. Related 8-Ks describe settlement mechanics, interest and installment payments, and the listing of the units under the symbol NOVTU. Other filings outline the terms of the company’s senior credit facilities under its Fourth Amended and Restated Credit Agreement and subsequent amendments, including leverage and coverage covenants.
Through this page, users can access Novanta’s 10-K annual reports and 10-Q quarterly reports (when filed), as well as Forms 4 and other ownership-related filings, via real-time updates from EDGAR. AI-powered summaries help explain complex sections, highlight key changes from prior periods, and clarify the implications of items such as guidance revisions, credit agreement provisions, and share repurchase programs.
Whether reviewing earnings-related disclosures, tracking capital structure developments, or examining governance and compensation information, this filings hub provides a structured entry point into Novanta’s SEC reporting history.
A holder of Novanta, Inc. common stock filed a notice to sell 6,177 shares through Merrill Private Wealth Management on the NASDAQ market. The filing reports an aggregate market value of 803,010 for these shares, compared with 35,775,123 common shares outstanding. The seller acquired the 6,177 shares as restricted stock units from Novanta on 01/02/2024 as equity compensation. The notice also discloses that the same person sold 323 common shares for gross proceeds of 41,990 on 01/08/2026.
A holder has filed a notice of proposed sale under Rule 144 for 323 shares of Novanta, Inc. common stock. The shares are planned to be sold on or about 01/08/2026 on the NASDAQ market through Merrill Private Wealth Management. The filing notes that 35,775,123 shares of Novanta common stock were outstanding. These 323 shares were originally acquired on 01/02/2024 as restricted stock units from Novanta, Inc. as a form of equity compensation, with payment also dated 01/02/2024 and described as equity compensation.
Novanta Inc. director Wilson Frank Anders reported equity award activity on January 2, 2026. He settled 1,325 Restricted Stock Units (RSUs), which were each the economic equivalent of one Novanta common share, into 1,325 shares of common stock, bringing his directly held common stock to 3,947 shares following the transaction.
On the same date, he received a new grant of 1,799 RSUs, each representing the right to receive one Novanta common share on the first anniversary of the grant date (or the next business day). These RSUs were fully vested and non‑forfeitable on the grant date, leaving him with 1,799 RSUs beneficially owned after the reported transactions.
Novanta Inc. director Mauricio Maxine Lum reported equity compensation activity involving restricted stock units (RSUs) and common shares. On January 2, 2026, 1,325 RSUs, each equal to one Novanta common share, were settled into 1,325 shares of common stock at a reported price of $0 per share, bringing Lum’s directly held common stock to 4,548 shares.
On the same date, Lum received a new award of 1,799 RSUs. Each of these RSUs represents the right to receive one Novanta common share on the first anniversary of the grant date (or the next business day). The filing notes that these RSUs were fully vested and non-forfeitable on the grant date and that Lum now directly holds 1,799 RSUs after the reported transactions.
Novanta Inc. director Darlene J. S. Solomon reported restricted stock unit activity and related common share ownership changes. On January 2, 2026, 1,325 restricted stock units were settled into 1,325 Novanta common shares at a price of $0 per share, leaving her with 3,541 common shares held directly. The filing also reports a grant of 1,799 restricted stock units on the same date, each representing the right to receive one Novanta common share on the first anniversary of the grant date. These newly granted units were fully vested and non-forfeitable on the grant date, and she holds 1,799 restricted stock units directly after the transactions.
Novanta Inc. director Thomas N. Secor reported equity-related transactions in company stock. On January 2, 2026, 1,325 Restricted Stock Units (RSUs) were settled into 1,325 shares of Novanta common stock at a reported price of $0.00 per share, leaving him with 1,325 common shares held directly. Each RSU was the economic equivalent of one common share.
On the same date, Secor was also awarded 1,799 new RSUs at a price of $0.00, with each unit representing the right to receive one Novanta common share on the first anniversary of the grant date (or the next business day). The filing notes that these RSUs were fully vested and non‑forfeitable on the grant date.
Novanta Inc. director Robert Matthew Johnson reported routine equity compensation activity. On January 2, 2026, 1,325 Restricted Stock Units (RSUs), each equivalent to one Novanta common share, were settled into 1,325 shares of common stock. After this settlement, he directly held 2,143 shares of common stock.
On the same date, Johnson was granted 1,799 new RSUs, each representing the right to receive one Novanta common share on the first anniversary of the grant date (or the next business day). These RSUs were fully vested and non‑forfeitable at grant, and he held 1,799 derivative securities (RSUs) directly following the grant.
Novanta Inc. director Lonny J. Carpenter reported equity awards and a share settlement. On January 2, 2026, he received 1,799 Restricted Stock Units (RSUs), each representing the right to receive one Novanta common share, with no cash paid per unit. On the same date, 1,325 previously held RSUs were settled into 1,325 shares of common stock, reflecting that each RSU was the economic equivalent of one common share and had become fully vested and non‑forfeitable. Following these transactions, Carpenter directly owned 5,848 shares of common stock and held 1,799 RSUs outstanding.
Novanta Inc. director reported a small stock sale under a pre-arranged trading plan. On 12/15/2025, the reporting person sold 748 shares of Novanta common stock at a price of $119.67 per share. After this transaction, the director directly beneficially owns 747 shares of Novanta common stock. The filing notes that the sale was carried out under a pre-established Rule 10b5-1 trading plan adopted on September 10, 2025, which is designed to allow insiders to sell shares according to a preset schedule.
Novanta Inc. (NOVT) revised its guidance following a recent equity issuance. The company lowered non-GAAP Adjusted Diluted EPS guidance to $0.84–$0.91 for Q4 2025 and $3.21–$3.28 for full-year 2025, compared with prior ranges of $0.87–$0.93 and $3.24–$3.30.
Revenue and Adjusted EBITDA guidance remain unchanged. GAAP revenue is still $253–$257 million for Q4 2025 and $975–$979 million for the year. Adjusted EBITDA remains $62–$65 million for Q4 and $222–$225 million for full-year 2025.
The guidance reflects higher diluted share counts from the equity issuance: an expected impact of 2.5–2.6 million shares in Q4 2025 and 0.6–0.7 million for full-year 2025, with an estimated 2026 impact of 4.7–5.9 million shares.